Status:
RECRUITING
Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery
Lead Sponsor:
Zhejiang University
Conditions:
Tumor of Pancreas
Surgical Blood Loss
Eligibility:
All Genders
14-70 years
Phase:
NA
Brief Summary
Pancreatic enucleation could preserve more healthy pancreatic tissues and functions with a low recurrence risk. However, conventional enucleation can cause significant intraoperative bleeding, especia...
Detailed Description
Between March 2023 and May 2026, patients who underwent laparoscopic pancreatic enucleation by blocking both the abdominal trunk and superior mesenteric artery in the Second Affiliated Hospital of Zhe...
Eligibility Criteria
Inclusion
- Benign or borderline tumors diagnosed pathologically, such as pancreatic neuroendocrine tumors, solid pseudopapillary tumors, and cystadenomas, without vascular invasion or distant metastasis
- Tumors sited in the pancreatic head, neck, and uncinate process of pancreas
- Blockade of both the abdominal trunk and superior mesenteric artery in the laparoscopic enucleation
Exclusion
- Highly malignant pancreatic tumors, or tumors with infiltration or metastasis
- Tumors of the body and tail of the pancreas
- Transfer to LPD or laparotomy
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06164769
Start Date
March 1 2023
End Date
June 30 2026
Last Update
June 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310000